

Individual Laboratory Report - Lab 1840

OVARIAN and PROSTATE CANCER (v Somatic) [PARPi] | 2025

SUMMARY OF YOUR PERFORMANCE IN THIS EQA

Assessment Category	Performance (mean score) ¹
Genotyping	2.00
Interpretation	2.00
Patient Identifiers and Clerical Accuracy	1.50
EQA Result (PASS or POOR)	PASS

CASE SPECIFIC FEEDBACK

Case 1

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0)
Interpretation	2.00	All essential interpretative elements provided. No deductions. (0)
Patient Identifiers and Clerical Accuracy	1.50	Incorrect or missing patient sex (0.5) According to best practice guidelines you should add patient gender in the patient information

Case 2

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	2.00	Correct result reported (0) According to best practice guidelines you should add patient gender in the patient information
Interpretation	2.00	All essential interpretative elements provided. No deductions. (0)
Patient Identifiers and Clerical Accuracy	1.50	Incorrect or missing patient sex (0.5)

Key: ¹ **Green** (Pass), **Red** (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>

1840



4367


Case 3

Assessment Category	Score ²	Comments (& deductions) ³
Genotyping	0.00	Correct result reported (0) Not marked
Interpretation	2.00	All essential interpretative elements provided. No deductions. (0)
Patient Identifiers and Clerical Accuracy	1.50	Incorrect or missing patient sex (0.5) According to best practice guidelines you should add patient gender in the patient information

This Individual Laboratory Report should be read in conjunction with scheme summary report.

Thank you for participating in this year's EQA, we look forward to you participating again next year.

Report approved and authorised by Simon Patton (19 June 2026) on behalf of EMQN.



Dr. Simon Patton (CEO)

Key: ¹ **Green** (Pass), **Red** (Poor performance), NRS (no results submitted), WDS (withdrew from scheme)

² Maximum score is 2.00

³ Deductions from the maximum score

EMQN CIC is an incorporated Community Interest Company registered in England and Wales (registration no: 12020789), which provides external quality assessment schemes for genomic diagnostic testing laboratories. EMQN is a UKAS accredited proficiency testing provider, No. 4367 and our registered address is Third Floor, ICE Building, 3 Exchange Quay, Salford, M5 3ED, United Kingdom.

Email: office@emqn.org Web: <https://www.emqn.org/>

1840



4367